No adverse events observed as study begins in EGFR‑mutant NSCLC
Author: Clinical Editor
First immunotherapy approved for LACC in England offers new treatment option for women
Updated Date: Wed, 17 Jun 2026 00:00:00 EDT
Updated Date: Tue, 16 Jun 2026 00:00:00 EDT
Updated Date: Tue, 16 Jun 2026 00:00:00 EDT
Updated Date: Tue, 16 Jun 2026 00:00:00 EDT
Lundbeck will present new migraine data at the European Academy of Neurology Congress 2026, taking place from 27–30 […]
FDA alignment secured as company prepares to begin dosing in 2026
Updated Date: Tue, 16 Jun 2026 00:00:00 EDT
Updated Date: Tue, 16 Jun 2026 00:00:00 EDT